Wells Fargo has downgraded its rating for Halozyme Therapeutics (HALO, Financial), a U.S. biotechnology company, from "Overweight" to "Equal Weight," with a target price set at $62, indicating limited upside potential. This year, Halozyme's stock has surged by 50%, compared to the S&P 500's approximately 21% rise. As of the close of trading on Monday, Halozyme's shares fell 9% to $53.85. While new product launches present a reason for holding Halozyme stock, Wells Fargo believes that market expectations alr ...

Have you been searching for a stock that might be well-positioned to maintain its earnings-beat streak in its upcoming report? It is worth considering Halozyme Therapeutics (HALO) , which belongs to the Zacks Medical - Biomedical and Genetics industry. When looking at the last two reports, this biopharmaceutical company has recorded a strong streak of surpassing earnings estimates. The company has topped estimates by 15.58%, on average, in the last two quarters. For the most recent quarter, Halozyme Therape ...

It has been about a month since the last earnings report for Halozyme Therapeutics (HALO) . Shares have added about 14.8% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading up to its next earnings release, or is Halozyme Therapeutics due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important drivers. Halozyme's Q2 Earnings & ...

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both. The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens. Zacks Premium includes access to the Zacks Style Scores as well. What are the Zacks Style Scores? ...

SAN DIEGO, Aug. 28, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Dr. Helen Torley, President and Chief Executive Officer, and Tram Bui, VP of Investor Relations and Corporate Communications, are scheduled to present and host investor meetings at the following investor conferences. Details of the presentations are as follow: Event: 2024 Wells Fargo Healthcare Conference Format: Fireside Chat and 1x1 Meetings Presentation Date: Wednesday, September 4, 2024 ...

FX Empire Logo English check-icon Italiano Español Português Deutsch العربية Français Important DisclaimersThe content provided on the website includes general news and publications, our personal analysis and opinions, and contents provided by third parties, which are intended for educational and research purposes only. It does not constitute, and should not be read as, any recommendation or advice to take any action whatsoever, including to make any investment or buy any product. When making any financial ...

J Studios/DigitalVision via Getty Images Investment Thesis In my search to find the best companies, I evaluate publicly traded companies in a wide variety of sectors and industries. Previously I have evaluated consumer discretionary companies like restaurants and cruise lines, however, with experience in cell and molecular biology, I can apply this knowledge to evaluate companies in biotech to see if they warrant further investment. Based on the fundamental analysis below, Halozyme Therapeutics, Inc. (NASDA ...

12 August 2024 | 2:31AM EDT 2131d4eaf4cb4d50b1d51c8af07b64b4 Halozyme Therapeutics Inc. (HALO): What is the potential upside on pending launches, new partnerships? HALO's revenue and cash flows are primarily (and increasingly) driven by royalty revenues on Enhanze partnered products, which offer predictable and high margin growth, consistent with management guidance through 2028. However, we frequently field questions on where there is potential discovery value on this platform, thus we highlight two avenue ...

Halozyme Therapeutics, Inc. (HALO) reported second-quarter 2024 adjusted earnings of 91 cents per share, which surpassed the Zacks Consensus Estimate of 78 cents. The company had recorded earnings of 74 cents per share in the year-ago period. Total revenues increased almost 5% year over year to $231.4 million in the second quarter. Revenues surpassed the Zacks Consensus Estimate of $211 million. The top line was driven by higher royalty payments from Roche (RHHBY) for Phesgo and higher sales of proprietary ...

| --- | --- | |---------------------------------------------------|-------| | | | | Halozyme Therapeutics, Inc. | | | Second Quarter 2024 Financial & Operating Results | | | NASDAQ: HALO | | | | | | August 6, 2024 | | | | | 1 Forward Looking Statements In addition to historical information, the statements set forth in this presentation include forward-looking statements including, without limitation, statements concerning the Company's expected future growth, financial performance (including the Company's 2 ...